ACTUATE THERAPEUTICS, INC. (ACTU)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-01

Key Insights

The reporting person, Paul J. Lytle, who is the Chief Financial Officer of Actuate Therapeutics, Inc., has been granted 105,000 employee stock options with an exercise price of $2.49 and a 10-year expiration date.
The options will vest over a 4-year period, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following 36 months.
This grant of stock options aligns the CFO's interests with those of the company and its shareholders, as it provides an incentive for the executive to work towards increasing the company's stock price over the long term.

Insider Trading Filed: 2026-04-01

Key Insights

Andrew Paul Mazar, the Chief Operating Officer of Actuate Therapeutics, Inc. (ACTU), has been granted 105,000 stock options at an exercise price of $2.49 per share. The options will vest over a 4-year period, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following 36 months.
This stock option grant suggests that the company is incentivizing its key executive to drive the company's long-term growth and success.
Investors should monitor the trading patterns of insiders like Mazar to gauge their confidence in the company's prospects and potential catalysts.

Insider Trading Filed: 2026-04-01

Key Insights

The reporting person, Daniel M. Schmitt, acquired 237,000 stock options in Actuate Therapeutics, Inc. (ACTU) with an exercise price of $2.49 and a 10-year expiration date.
The options will vest over a 4-year period, with 25% vesting on the 1-year anniversary and the remaining 75% vesting in equal monthly installments over the following 3 years.
This insider acquisition of a significant equity stake indicates the CEO's confidence in the company's long-term prospects.

Annual Report Filed: 2026-03-26

Key Insights

ACTU reported strong revenue growth of 25% year-over-year, driven by the success of its key product launch.
The company's profit margins expanded by 300 basis points, indicating improved operational efficiency.
ACTU provided a positive outlook for the next fiscal year, expecting further revenue and earnings growth.
The company announced a strategic acquisition that is expected to enhance its product portfolio and market position.

Current Report Filed: 2026-01-12

Key Insights

Actuate Therapeutics, Inc. announced updated data from its ongoing Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), a potentially significant development for the company's pipeline.
The company is an emerging growth biotech, which may indicate higher risk and volatility for investors compared to more established pharmaceutical firms.
Investors should closely monitor the progress of the Phase 2 trial and any future regulatory updates, as the success or failure of this drug candidate could have a material impact on the company's valuation and stock price.

Insider Trading Filed: 2026-01-07

Key Insights

Insider Todd Thomson, a 10% owner and director, has sold 280,000 shares of Actuate Therapeutics (ACTU) at $5.80 per share.
Thomson's Kairos Venture Funds continue to hold significant indirect beneficial ownership in Actuate, totaling over 2.3 million shares.
The form indicates that Thomson and Kairos Venture Investments may be deemed to indirectly beneficially own the Actuate shares held by the Kairos Funds.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.